VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA
局部晚期或转移性黑色素瘤的疫苗治疗和/或 GM-CSF
基本信息
- 批准号:7375529
- 负责人:
- 金额:$ 0.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-12-01 至 2006-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known which treatment regimen is more effective for melanoma. This randomized Phase III trial is studying peptide vaccine therapy and/or sargramostim and comparing how well they work in treating patients with locally advanced or metastatic melanoma. Since it is not known if any of these treatments are effective for melanoma patients who have been surgically rendered free of disease, but who remain at very high risk for disease recurrence, this study is placebo controlled. Thus, some patients will receive the experimental treatment and some patients will receive a placebo. The treatments will be compared to see if any of these treatments help melanoma patients live longer or have a longer time before the melanoma recurs.
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。疫苗可以使身体产生免疫反应来杀死肿瘤细胞。集落刺激因子,如沙格拉莫stim,可增加骨髓或外周血中免疫细胞的数量。目前尚不清楚哪种治疗方案对黑色素瘤更有效。这项随机III期试验正在研究肽疫苗疗法和/或sargramostim,并比较它们在治疗局部晚期或转移性黑色素瘤患者中的效果。由于目前尚不清楚这些治疗方法是否对手术治愈的黑色素瘤患者有效,但这些患者仍有很高的疾病复发风险,因此本研究采用安慰剂对照。因此,一些患者将接受实验性治疗,而一些患者将接受安慰剂。将对这些治疗方法进行比较,看看这些治疗方法是否能帮助黑色素瘤患者活得更长,或者在黑色素瘤复发之前有更长的时间。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK R ALBERTINI其他文献
MARK R ALBERTINI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK R ALBERTINI', 18)}}的其他基金
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
瘤内注射免疫细胞因子激活自发性犬黑色素瘤的免疫排斥
- 批准号:
9557995 - 财政年份:2019
- 资助金额:
$ 0.31万 - 项目类别:
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
瘤内注射免疫细胞因子激活自发性犬黑色素瘤的免疫排斥
- 批准号:
10515319 - 财政年份:2019
- 资助金额:
$ 0.31万 - 项目类别:
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
瘤内注射免疫细胞因子激活自发性犬黑色素瘤的免疫排斥
- 批准号:
10815692 - 财政年份:2019
- 资助金额:
$ 0.31万 - 项目类别:
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
瘤内注射免疫细胞因子激活自发性犬黑色素瘤的免疫排斥
- 批准号:
10266001 - 财政年份:2019
- 资助金额:
$ 0.31万 - 项目类别:
VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA
局部晚期或转移性黑色素瘤的疫苗治疗和/或 GM-CSF
- 批准号:
7607523 - 财政年份:2006
- 资助金额:
$ 0.31万 - 项目类别:
HIGH-DOSE IFN-ALPHA-2B VS CISPLATIN, VINBLASTINE, DTIC + IL-2 & IFN IN MELANOMA
高剂量 IFN-ALPHA-2B 与顺铂、长春碱、DTIC IL-2
- 批准号:
7607496 - 财政年份:2006
- 资助金额:
$ 0.31万 - 项目类别:
HIGH-DOSE IFN-ALPHA-2B VS CISPLATIN, VINBLASTINE, DTIC + IL-2 & IFN IN MELANOMA
高剂量 IFN-ALPHA-2B 与顺铂、长春碱、DTIC IL-2
- 批准号:
7375486 - 财政年份:2005
- 资助金额:
$ 0.31万 - 项目类别:
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T
HU14 18 IL 2 融合蛋白在 GD2 T 患者中的 I/IB 期试验
- 批准号:
6568840 - 财政年份:2001
- 资助金额:
$ 0.31万 - 项目类别:
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T
HU14 18 IL 2 融合蛋白在 GD2 T 患者中的 I/IB 期试验
- 批准号:
6468963 - 财政年份:2000
- 资助金额:
$ 0.31万 - 项目类别:
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T
HU14 18 IL 2 融合蛋白在 GD2 T 患者中的 I/IB 期试验
- 批准号:
6411646 - 财政年份:2000
- 资助金额:
$ 0.31万 - 项目类别:
相似海外基金
New efficacy of inhaled GM-CSF therapy.
吸入 GM-CSF 疗法的新功效。
- 批准号:
20H03688 - 财政年份:2020
- 资助金额:
$ 0.31万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Novel protocols of inhaled GM-CSF therapy for smoker patients with pulmonary alveolar proteinosis
吸入 GM-CSF 治疗吸烟者肺泡蛋白沉积症的新方案
- 批准号:
20H03686 - 财政年份:2020
- 资助金额:
$ 0.31万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidation of GM-CSF expression regulation mechanism by amino acid-mTORC1 and its application to psoriasis therapy
氨基酸-mTORC1阐明GM-CSF表达调控机制及其在银屑病治疗中的应用
- 批准号:
17K08893 - 财政年份:2017
- 资助金额:
$ 0.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study on dry cow therapy with bovine GM-CSF produced in transgenic silkworm for experimental bovine mastitis.
转基因蚕产生的牛GM-CSF干奶疗法治疗实验性牛乳腺炎的研究。
- 批准号:
16K08065 - 财政年份:2016
- 资助金额:
$ 0.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Phytogene therapy development with RNAi mediated gene silencing in crops for disease control without GM
利用 RNAi 介导的作物基因沉默技术开发 Phytogene 疗法,用于无需转基因的疾病控制
- 批准号:
BB/N503897/1 - 财政年份:2015
- 资助金额:
$ 0.31万 - 项目类别:
Training Grant
Phytogene therapy development with RNAi mediated gene silencing in crops for disease control without GM
利用 RNAi 介导的作物基因沉默技术开发 Phytogene 疗法,用于无需转基因的疾病控制
- 批准号:
1668266 - 财政年份:2015
- 资助金额:
$ 0.31万 - 项目类别:
Studentship
STING-Activating GM-CSF Secreting Allogeneic Pancreas Tumor Cell Vaccine Therapy
STING 激活 GM-CSF 分泌同种异体胰腺肿瘤细胞疫苗疗法
- 批准号:
8715590 - 财政年份:2014
- 资助金额:
$ 0.31万 - 项目类别:
Pulmonary Alveolar Proteinosis (PAP) and Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Therapy--ClinicalFeatures Predicting Response and Recurrence.
肺泡蛋白沉积症 (PAP) 和吸入粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 治疗 - 预测反应和复发的临床特征。
- 批准号:
22590852 - 财政年份:2010
- 资助金额:
$ 0.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeting the shared beta-chain of the IL-3, IL-5 and GM-CSF receptors as therapy for allergic inflammation
靶向 IL-3、IL-5 和 GM-CSF 受体的共享 β 链作为过敏性炎症的治疗方法
- 批准号:
nhmrc : 510716 - 财政年份:2008
- 资助金额:
$ 0.31万 - 项目类别:
NHMRC Project Grants
VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA
局部晚期或转移性黑色素瘤的疫苗治疗和/或 GM-CSF
- 批准号:
7607523 - 财政年份:2006
- 资助金额:
$ 0.31万 - 项目类别: